Log in to search using one of your social media accounts:

 

Boehringer Ingelheim, Anthem partner for largest real-world COPD trial

As part of a research collaboration launched in 2014, Boehringer Ingelheim and Anthem have partnered to study people with chronic obstructive pulmonary disease in real-world settings to assess how commonly-prescribed drugs may reduce the occurrence of COPD exacerbations. The team, which also includes Anthem’s outcomes research subsidiary HealthCore, plans to investigate whether adding an inhaled corticosteroid to a LAMA-LABA combination provides a meaningful benefit – a question under debate in the respiratory space. Get the full story at our sister site, Drug Delivery Business News. The post Boehringer Ingelheim, Anthem partner for largest real-world COPD trial appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Anthem Inc. Boehringer Ingelheim Pharmaceuticals Source Type: news

Related Links:

This study is registered with ClinicalTrials.gov, number NCT02442206. Findings Between May 18, 2015, and April 20, 2017, we randomly assigned 62 eligible participants to treatment; 30 to indacaterol–glycopyrronium followed by placebo and 32 to placebo followed by indacaterol–glycopyrronium. The 62 randomly assigned patients were included in the intent-to-treat analysis. There were two protocol violations and therefore 60 were included in the per-protocol analysis. 57 patients completed both treatment periods. After indacaterol–glycopyrronium treatment, left-ventricular end-diastolic volume increased from ...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Authors: Wu J, Li X, Qin Y, Cheng J, Hao G, Jin R, Zhu C Abstract The aim of the present study was to investigate the effect of a Traditional Chinese Herbal Medicine (TCHM), named Jinwei Tang on histone deacetylase 2 (HDAC2) and its role in the regulation of corticosteroid resistance in a rat model of chronic obstructive pulmonary disease (COPD). Male Wistar rats were divided into five groups (each n=10): COPD group, established by the intratracheal instillation of lipopolysaccharide and passive smoke exposure, and control, budesonide, theophylline + budesonide and Jinwei Tang + budesonide groups. Lung function was...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Long - term inhaled corticosteroid use for COPD tied to small increased risk of hip, upper extremity fracture
Source: Pulmonary Medicine News - Doctors Lounge - Category: Respiratory Medicine Tags: Internal Medicine, Orthopedics, Pharmacy, Pulmonology, Journal, Source Type: news
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) have submitted data to the European Medicines Agency in the hopes of expanding the label for its once-daily, triple combination inhaler, Trelegy Ellipta. The drug-device combo was approved in Europe in November last year as a maintenance treatment for adult patients with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a inhaled corticosteroid combined with a long-acting beta-adrenergic agonist. GSK and Innoviva hope that data from its Impact trial will support the product’s use in a broader populati...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat GlaxoSmithKline plc Innoviva Source Type: news
CONCLUSIONS: In COPD patients with CVD or risk factors for CVD, exacerbations confer an increased risk of subsequent CVD events, especially in hospitalized patients and within the first 30 days post-exacerbation. Patients and clinicians should have heightened vigilance for early CVD events following AECOPD. Clinical trial registration available at www.clinicaltrials.gov, ID NCT01313676. PMID: 29442524 [PubMed - as supplied by publisher]
Source: American Journal of Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Tags: Am J Respir Crit Care Med Source Type: research
Abstract The mission of the Cochrane Nursing Care Field (CNCF) is to improve health outcomes through increasing the use of the Cochrane Library and supporting Cochrane's role by providing an evidence base for nurses and healthcare professionals who deliver, lead or research nursing care. The CNCF produces Cochrane Corner columns, summaries of recent nursing-care-relevant Cochrane Reviews that are regularly published in collaborating nursing-related journals. Information on the processes CNCF has developed can be accessed at: cncf.cochrane.org/evidence-transfer-program-review-summaries . This is a Cochrane review s...
Source: Nursing Standard - Category: Nursing Authors: Tags: Nurs Stand Source Type: research
TUESDAY, Feb. 13, 2018 -- Many patients with chronic obstructive pulmonary disease (COPD) are placed on powerful inhaled corticosteroid therapy to ease symptoms. But new research suggests the treatment might raise their odds for bone...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
Conclusions LAMA or ICS/LABA combinations use was associated with a lower risk of acute exacerbation in patients with COPD and asthma in this study.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Semin Respir Crit Care Med 2018; 39: 036-044 DOI: 10.1055/s-0037-1608707Strategies to control the risk domain of NHLBI EPR-3 (National Heart, Lung, and Blood Institute Expert Panel Report-3) asthma guidelines, which includes exacerbations requiring systemic corticosteroids, reduction in lung growth, and progressive loss of lung function, and treatment-related adverse effects, are evolving in children and adolescents. Increasing evidence demonstrates that children and adolescents with asthma are at risk of a reduction in lung growth, leading to lower lung function and potentially chronic obstructive pulmonary disease as adu...
Source: Seminars in Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Tags: Review Article Source Type: research
This study is registered with ClinicalTrials.gov, number NCT02579850. Findings Between May, 29 2015, and July 10, 2017, 1532 patients received BDP/FF/G (n=764) or IND/GLY (n=768). Moderate-to-severe exacerbation rates were 0·50 per patient per year (95% CI 0·45–0·57) for BDP/FF/G and 0·59 per patient per year (0·53–0·67) for IND/GLY, giving a rate ratio of 0·848 (0·723–0·995, p=0·043) in favour of BDP/FF/G. Adverse events were reported by 490 (64%) of 764 patients receiving BDP/FF/G and 516 (67%) of 768 patients receiving IND/GLY. Pneum...
Source: The Lancet - Category: General Medicine Source Type: research
More News: Chronic Obstructive Pulmonary | Clinical Trials | Corticosteroid Therapy | Respiratory Medicine | Study